Parameters
|
PD-1
|
PD-L1
|
PD-L2
|
---|
Positive (n = 18)
|
Negative (n = 43)
|
p value
|
Positive (n = 24)
|
Negative (n = 37)
|
p value
|
Positive (n = 20)
|
Negative (n = 41)
|
p value
|
---|
TNBC (n = 61)
|
Age at operation
|
≤ 56
|
4 (22.2%)
|
24 (55.8%)
|
0.016
|
10 (41.7%)
|
18 (48.6%)
|
0.593
|
12 (60.0%)
|
16 (39.0%)
|
0.123
|
> 56
|
14 (77.8%)
|
19 (44.2%)
|
14 (58.3%)
|
19 (51.4%)
|
8 (40.0%)
|
25 (61.0%)
|
Menopause
|
Negative
|
4 (22.2%)
|
18 (41.9%)
|
0.121
|
9 (37.5%)
|
13 (35.1%)
|
0.851
|
8 (40.0%)
|
14 (34.1%)
|
0.655
|
Positive
|
14 (77.8%)
|
25 (58.1%)
|
15 (62.5%)
|
24 (64.9%)
|
12 (60.0%)
|
27 (65.9%)
|
Tumor size (cm)
|
≤ 2
|
3 (16.7%)
|
4 (9.3%)
|
0.337
|
3 (12.5%)
|
4 (10.8%)
|
0.573
|
3 (15.0%)
|
4 (9.8%)
|
0.416
|
> 2
|
15 (83.3%)
|
39 (90.7%)
|
21 (87.5%)
|
33 (89.2%)
|
17 (85.0%)
|
37 (90.2%)
|
Lymph node status
|
Negative
|
3 (16.7%)
|
8 (18.6%)
|
0.586
|
5 (20.8%)
|
6 (16.2%)
|
0.647
|
3 (15.0%)
|
8 (19.5%)
|
0.481
|
Positive
|
15 (83.3%)
|
35 (81.4%)
|
19 (79.2%)
|
31 (83.8%)
|
17 (85.0%)
|
33 (80.5%)
|
Nuclear grade
|
1, 2
|
13 (72.2%)
|
31 (72.1%)
|
0.992
|
19 (79.2%)
|
25 (67.6%)
|
0.324
|
14 (70.0%)
|
30 (73.2%)
|
0.795
|
3
|
5 (27.8%)
|
12 (27.9%)
|
5 (20.8%)
|
12 (32.4%)
|
6 (30.0%)
|
11 (26.8%)
|
Ki67
|
≤ 14%
|
6 (33.3%)
|
12 (27.9%)
|
0.672
|
12 (50.0%)
|
6 (16.2%)
|
0.005
|
6 (30.0%)
|
12 (29.3%)
|
0.953
|
> 14%
|
12 (66.7%)
|
31 (72.1%)
|
12 (50.0%)
|
31 (83.8%)
|
14 (70.0%)
|
29 (70.7%)
|
Pathological response
|
pCR
|
3 (16.7%)
|
25 (58.1%)
|
0.003
|
3 (12.5%)
|
25 (67.6%)
|
< 0.001
|
10 (50.0%)
|
18 (43.9%)
|
0.654
|
Non-pCR
|
15 (83.3%)
|
18 (41.9%)
|
21 (87.5%)
|
12 (32.4%)
|
10 (50.0%)
|
23 (56.1%)
|
PD-1
|
Negative
|
Not determined
|
Not determined
| |
9 (37.5%)
|
34 (91.9%)
|
< 0.001
|
12 (60.0%)
|
31 (75.6%)
|
0.210
|
Positive
|
15 (62.5%)
|
3 (8.1%)
|
8 (40.0%)
|
10 (24.4%)
|
PD-L1
|
Negative
|
3 (16.7%)
|
34 (48.4%)
|
< 0.001
|
Not determined
|
Not determined
| |
10 (50.0%)
|
27 (65.9%)
|
0.234
|
Positive
|
15 (83.3%)
|
9 (51.6%)
| |
10 (50.0%)
|
14 (34.1%)
|
PD-L2
|
Negative
|
10 (55.6%)
|
31 (79.1%)
|
0.210
|
14 (58.3%)
|
27 (73.0%)
|
0.234
|
Not determined
|
Not determined
| |
Positive
|
8 (44.4%)
|
12 (20.9%)
|
10 (41.7%)
|
10 (27.0%)
|
Parameters
|
PD-1
|
PD-L1
|
PD-L2
|
---|
Positive (n = 3)
|
Negative (n = 42)
|
p value
|
Positive (n = 4)
|
Negative (n = 41)
|
p value
|
Positive (n = 16)
|
Negative (n = 29)
|
p value
|
---|
HER2+BC (n = 45)
|
Age at operation
|
≤ 56
|
0 (0.0%)
|
20 (47.6%)
|
0.162
|
1 (25.0%)
|
19 (46.3%)
|
0.394
|
6 (37.5%)
|
14 (48.3%)
|
0.486
|
> 56
|
3 (100.0%)
|
22 (52.4%)
|
3 (75.0%)
|
22 (53.7%)
|
10 (62.5%)
|
15 (51.7%)
|
Menopause
|
Negative
|
0 (0.0%)
|
18 (42.9%)
|
0.206
|
1 (25.0%)
|
17 (41.5%)
|
0.471
|
6 (37.5%)
|
12 (41.4%)
|
0.799
|
Positive
|
3 (100.0%)
|
24 (57.1%)
|
3 (75.0%)
|
24 (58.5%)
|
10 (62.5%)
|
17 (58.6%)
|
Tumor size (cm)
|
≤ 2
|
1 (33.3%)
|
5 (11.9%)
|
0.356
|
1 (25.0%)
|
5 (12.2%)
|
0.448
|
4 (25.0%)
|
2 (6.9%)
|
0.107
|
> 2
|
2 (66.7%)
|
37 (88.1%)
|
3 (75.0%)
|
36 (87.8%)
|
12 (75.0%)
|
27 (93.1%)
|
Lymph node status
|
Negative
|
1 (33.3%)
|
15 (35.7%)
|
0.715
|
2 (50.0%)
|
14 (34.2%)
|
0.448
|
5 (31.3%)
|
11 (37.9%)
|
0.455
|
Positive
|
2 (66.7%)
|
27 (64.3%)
|
2 (50.0%)
|
27 (65.8%)
|
11 (68.7%)
|
18 (62.1%)
|
Nuclear grade
|
1, 2
|
2 (66.7%)
|
33 (78.6%)
|
0.539
|
2 (50.0%)
|
33 (80.5%)
|
0.209
|
12 (75.0%)
|
23 (79.3%)
|
0.508
|
3
|
1 (33.3%)
|
9 (21.4%)
|
2 (50.0%)
|
8 (19.5%)
|
4 (25.0%)
|
6 (20.7%)
|
Ki67
|
≤ 14%
|
1 (33.3%)
|
23 (54.8%)
|
0.449
|
1 (25.0%)
|
23 (56.1%)
|
0.254
|
7 (43.8%)
|
17 (58.6%)
|
0.338
|
> 14%
|
2 (66.7%)
|
19 (45.2%)
|
3 (75.0%)
|
18 (43.9%)
|
9 (56.2%)
|
12 (41.4%)
|
Pathological response
|
pCR
|
0 (0.0%)
|
18 (42.9%)
|
0.206
|
1 (25.0%)
|
17 (41.5%)
|
0.471
|
11 (62.5%)
|
7 (24.1%)
|
0.005
|
Non-pCR
|
3 (100.0%)
|
24 (57.1%)
|
3 (75.0%)
|
24 (58.5%)
|
5 (37.5%)
|
22 (75.9%)
|
PD-1
|
Negative
|
Not determined
|
Not determined
| |
1 (25.0%)
|
41 (100.0%)
|
< 0.001
|
13 (81.3%)
|
29 (100.0%)
|
0.039
|
Positive
|
3 (75.0%)
|
0 (0.0%)
|
3 (18.7%)
|
0 (0.0%)
|
PD-L1
|
Negative
|
0 (0.0%)
|
41 (97.6%)
|
< 0.001
|
Not determined
|
Not determined
| |
12 (75.0%)
|
29 (100.0%)
|
0.012
|
Positive
|
3 (100.0%)
|
1 (2.4%)
|
4 (25.0%)
|
0 (0.0%)
|
PD-L2
|
Negative
|
0 (0.0%)
|
29 (69.0%)
|
0.039
|
0 (0.0%)
|
29 (70.7%)
|
0.012
|
Not determined
|
Not determined
| |
Positive
|
3 (100.0%)
|
13 (31.0%)
|
4 (100.0%)
|
12 (29.3%)
|
- TNBC triple-negative breast cancer, HER2 human epidermal growth factor receptor 2, BC breast cancer, pCR pathological complete response, PD-1 programmed cell death-1, PD-L programmed cell death-ligand